Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 10/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655770 | 0.91 | EGFR (0.44) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4034950 | 0.84 | MAPK14 (0.49) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4036011 | 0.83 | TGFBR1 (0.63) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4033475 | 0.80 | MAPK14 (0.49) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4035730 | 0.78 | TGFBR1 (0.52) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4030407 | 0.78 | MAPK14 (0.42) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4032576 | 0.78 | MAPK14 (0.44) | TGFBR1KDRMAPK10MAPK8CCNE1 | |
| SCHEMBL4030553 | 0.76 | TGFBR1 (0.67) | TGFBR1KDRMAPK14 | |
| SCHEMBL6831731 | 0.76 | MAPK10 (0.53) | KDRMAPK10MAPK8CDK2MAPK14 | |
| SCHEMBL4030453 | 0.76 | MAPK14 (0.44) | TGFBR1KDRMAPK10MAPK8CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542994-B1 | NOVEL OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | PFIZER PROD INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7273936-B2 | Oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1542994-A1 | NOVEL TRIAZOLE AND OXAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITOR | Pfizer Products Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
| WO-2004026863-A1 | NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110797-A1 | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors | TGFBR1, TGFBR2, SMAD3 | TGFBR1 1/4885KDR 293/4885MAPK10 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.